Company Shares of Ampio Pharmaceuticals (NYSEMKT:AMPE) Drops by -15.5%

Ampio Pharmaceuticals (NYSEMKT:AMPE) : During the past 4 weeks, traders have been relatively bearish on Ampio Pharmaceuticals (NYSEMKT:AMPE), hence the stock is down -70.77% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -16.57% relative to the S&P 500. The 4-week change in the price of the stock is -70.3% and the stock has fallen -15.5% in the past 1 week.

The company shares have dropped -58.56% from its 1 Year high price. On May 3, 2016, the shares registered one year high at $4.32 and the one year low was seen on Jun 30, 2016. The 50-Day Moving Average price is $3.21 and the 200 Day Moving Average price is recorded at $2.92.

The stock has recorded a 20-day Moving Average of 62.17% and the 50-Day Moving Average is 69.03%.


Ampio Pharmaceuticals (NYSEMKT:AMPE): On Fridays trading session , Opening price of the stock was $1.13 with an intraday high of $1.15. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $1.05. However, the stock managed to close at $1.09, a loss of 5.22% for the day. On the previous day, the stock had closed at $1.15. The total traded volume of the day was 2,079,222 shares.

Ampio Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused primarily on the development of therapies to treat prevalent inflammatory conditions. The Companys two lead product candidates in development are Ampion for osteoarthritis of the knee and Optina for diabetic macular edema. The Company is also focused on developing and monetizing its Oxidation Reduction Potential (ORP) diagnostic device and sexual dysfunction portfolio. Ampion is a sub 5000 molecular weight fraction of commercial human serum albumin (HSA) for the treatment of osteoarthritis and other inflammatory conditions. Optina is a low-dose formulation of danazol for the treatment of diabetic macular edema (DME). The Companys subsidiaries include Luoxis Diagnostics, Inc. (Luoxis), an in-vitro diagnostics company, and Vyrix Pharmaceuticals, Inc. (Vyrix), a specialty pharmaceutical company.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.